Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes (NCT06267391)
A Multicenter, Randomized, Double-blind, Sham-controlled Study for Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes (ReCET Study)
🩺 Plain-English Summary (8th-Grade Level)
This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.
Who can join: Review the eligibility criteria below.
Location: University of Alabama — Birmingham, Alabama
Age range: 22 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (44 Sites)
Showing the first 25 of 44 sites.
- University of Alabama — Birmingham, Alabama
- Central Alabama Research — Birmingham, Alabama
- Velocity Clinical Research, Gardena — Gardena, California
- Cedars-Sinai Medical Center — Los Angeles, California
- UCLA — Los Angeles, California
- Hoag Memorial Hospital Presbyterian - Digestive Health Institute — Newport Beach, California
- Velocity Clinical Research, Hallandale Beach — Hallandale, Florida
- Mayo Clinic — Jacksonville, Florida
- Universal Axon Clinical Research LLC — Miami, Florida
- University of Miami — Miami, Florida
- Quantum Clinical Research — Miami Beach, Florida
- West Orange Endocrinology — Ocoee, Florida
- Advent Health — Orlando, Florida
- Orlando Health — Orlando, Florida
- Health Synergy Clinical Research — West Palm Beach, Florida
- NorthShore University Health System — Evanston, Illinois
- Heartland Medical Research, Inc. — Clive, Iowa
- Iowa Diabetes and Endocrinology Research Center — West Des Moines, Iowa
- John Hopkins — Baltimore, Maryland
- Mayo Clinic — Rochester, Minnesota
- Cooper Health System — Camden, New Jersey
- Robert Wood Johnson Medical School — New Brunswick, New Jersey
- The Ohio State University- Wexner Medical Center — Columbus, Ohio
- Velocity Clinical Research - Austin — Austin, Texas
- Dell Medical School — Austin, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Type 2 Diabetes Mellitus
- Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study — Aurora, Colorado
- A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes — Tucson, Arizona
- Preventing Type 2 Diabetes in Black Emergent Adult — Chapel Hill, North Carolina
- Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease — Huntsville, Alabama
- GLP-1 and Hypoglycemia — Baltimore, Maryland
Explore by condition: All Type 2 Diabetes Mellitus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.